LPTX

Cypherpunk Technologies Inc. (LPTX) | Rumor.io

Cypherpunk Technologies

LPTX

Attention (50-day avg)0%

Attention rank (50-day avg)#4,874

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.28

Market capitalization233.4M

Earnings per share-1.58

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-67.6M

Social

What share of all stock conversation is about LPTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 8

Leap Therapeutics, Inc. ($LPTX) is a high conviction stock today with a score of 84/100.
The company's stock is being considered for potential investment.
The pre-market stock market is being monitored for movement in $LPTX.

Generated by AI

Sentiment

Of the messages about LPTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	81.94% +14.92
Bearish	—	—	—	18.06% -14.92

Bullish· Nov 12

Leap Therapeutics, now rebranded as Cypherpunk Technologies, has made a significant investment in Zcash, more than doubling its initial $50M investment.
The company's decision to rebrand and invest in Zcash has led to a substantial surge in the stock price of Leap Therapeutics, with some posts highlighting a 170% increase.
The rebranding and investment in Zcash are seen as bullish indicators for the company, with some traders expressing excitement about the potential for further growth and momentum in the stock.

Bearish· Jan 28

The company's DKN-01 drug has failed, and the stock price has plummeted as a result, with some predicting further declines.
The company's CRC data is far from convincing, with a 35% ORR vs 23% for bev/chemo, which may narrow in phase 3, raising concerns about the drug's efficacy.
The company's management is pushing to advance the failed DKN-01 drug to phase 3, which could lead to further dilution and a significant decline in the stock price.

Generated by AI

Topics

Of the messages about LPTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	39.54%
Announcements	—	—	—	19.02%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	32.76%
Technical Analysis	—	—	—	8.68%

Oct 6

Leap Therapeutics, Inc. (LPTX) announced a $58.88 million private placement led by Winklevoss Capital to establish a digital asset treasury strategy.
The private placement adds runway for the company and may indicate strategic alternatives, including a potential merger or sale.
The announcement led to a significant stock price increase, but equity dilution and strategic disputes heighten uncertainty, with a recommendation to short-term profit-taking or a neutral sell.

Generated by AI

Community

Of the messages about LPTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	23.52%
Newcomers	—	—	—	76.48%

Regulars· Oct 6

The recent $58.88 million private placement in cash commitments led by Winklevoss Capital may initiate a digital asset treasury strategy for Leap Therapeutics.
The company's Phase 2 DeFianCe trial shows promising results, with ORR and PFS gains in key subgroups, which could be a catalyst for a strong rally.
A potential merger or sale could be on the horizon, given the company's strategic alternatives and the recent PIPE financing adding runway.

Newcomers· Nov 17

Newcomers to $LPTX are discussing the stock's potential for growth, with one user highlighting a +22.7% increase in price.
Users are focusing on the stock's performance, with one user calling it a "sector standout" due to its predictable growth and real demand.
Another newcomer is sizing in on $LPTX due to seeing contracts, PPAs, and real infrastructure in motion, which they believe will drive the stock's growth.

Generated by AI

Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), today announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research.

1mo agoYahoo Finance

Also Discussed

Investors talking about LPTX also mention

#	Name	Attention
1	ACHL - Achilles Therapeutics plc	——
2	AFMD - Affimed N.V.	——
3	Korro Bio Inc.KRRO	0%0
4	Pavmed Inc.PAVM	0%0
5	BGNE - BeiGene, Ltd.	——
6	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
7	ONCT - Oncternal Therapeutics, Inc.	——
8	PDS Biotechnology CorporationPDSB	0.01%-0.01
9	ALX Oncology Holdings Inc.ALXO	0%0
10	Adaptimmune Therapeutics plc ADRADAP	0%0

Cypherpunk Technologies Inc.

Financial Services
Asset Management

Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches. The company’s lead clinical-stage candidate, DKN-01, is a monoclonal antibody designed to inhibit Dickkopf-related protein 1 and is currently being evaluated in multiple clinical trials for esophagogastric, gynecologic, and colorectal cancers. Additional pipeline assets include FL-301, targeting Claudin18.2-expressing cells, and preclinical programs FL-302 and FL-501. Cypherpunk Technologies also distinguishes itself with a unique digital asset treasury strategy, actively acquiring and holding Zcash (ZEC) as part of its long-term value-building initiative. The company’s research and development operations are conducted through its wholly-owned subsidiary, Leap Therapeutics, Inc. Headquartered in Cambridge, Massachusetts, Cypherpunk Technologies operates at the intersection of biotechnology innovation and digital asset investment, reflecting its dual commitment to advancing cancer therapies and supporting privacy-focused technologies.

Website

Location

47 Thorndike Street

Cambridge, MA, 02141

United States

Social

What share of all stock conversation is about LPTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 8

Leap Therapeutics, Inc. ($LPTX) is a high conviction stock today with a score of 84/100.
The company's stock is being considered for potential investment.
The pre-market stock market is being monitored for movement in $LPTX.

Generated by AI

Sentiment

Of the messages about LPTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	81.94% +14.92
Bearish	—	—	—	18.06% -14.92

Bullish· Nov 12

Leap Therapeutics, now rebranded as Cypherpunk Technologies, has made a significant investment in Zcash, more than doubling its initial $50M investment.
The company's decision to rebrand and invest in Zcash has led to a substantial surge in the stock price of Leap Therapeutics, with some posts highlighting a 170% increase.
The rebranding and investment in Zcash are seen as bullish indicators for the company, with some traders expressing excitement about the potential for further growth and momentum in the stock.

Bearish· Jan 28

The company's DKN-01 drug has failed, and the stock price has plummeted as a result, with some predicting further declines.
The company's CRC data is far from convincing, with a 35% ORR vs 23% for bev/chemo, which may narrow in phase 3, raising concerns about the drug's efficacy.
The company's management is pushing to advance the failed DKN-01 drug to phase 3, which could lead to further dilution and a significant decline in the stock price.

Generated by AI

Topics

Of the messages about LPTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	39.54%
Announcements	—	—	—	19.02%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	32.76%
Technical Analysis	—	—	—	8.68%

Oct 6

Leap Therapeutics, Inc. (LPTX) announced a $58.88 million private placement led by Winklevoss Capital to establish a digital asset treasury strategy.
The private placement adds runway for the company and may indicate strategic alternatives, including a potential merger or sale.
The announcement led to a significant stock price increase, but equity dilution and strategic disputes heighten uncertainty, with a recommendation to short-term profit-taking or a neutral sell.

Generated by AI

Community

Of the messages about LPTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	23.52%
Newcomers	—	—	—	76.48%

Regulars· Oct 6

The recent $58.88 million private placement in cash commitments led by Winklevoss Capital may initiate a digital asset treasury strategy for Leap Therapeutics.
The company's Phase 2 DeFianCe trial shows promising results, with ORR and PFS gains in key subgroups, which could be a catalyst for a strong rally.
A potential merger or sale could be on the horizon, given the company's strategic alternatives and the recent PIPE financing adding runway.

Newcomers· Nov 17

Newcomers to $LPTX are discussing the stock's potential for growth, with one user highlighting a +22.7% increase in price.
Users are focusing on the stock's performance, with one user calling it a "sector standout" due to its predictable growth and real demand.
Another newcomer is sizing in on $LPTX due to seeing contracts, PPAs, and real infrastructure in motion, which they believe will drive the stock's growth.

Generated by AI

Cypherpunk Technologies

Social

Dec 8

Sentiment

Bullish· Nov 12

Bearish· Jan 28

Topics

Oct 6

Community

Regulars· Oct 6

Newcomers· Nov 17

News

Leap Therapeutics publishes DeFianCe trial results in journal

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Also Discussed

Cypherpunk Technologies Inc.

Company Information

Location

News

Leap Therapeutics publishes DeFianCe trial results in journal

Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Also Discussed

Social

Dec 8

Sentiment

Bullish· Nov 12

Bearish· Jan 28

Topics

Oct 6

Community

Regulars· Oct 6

Newcomers· Nov 17